News
Named for five consecutive years | Warmest congratulations to Wanbang Xinnuokang® Ginkgo Leaf Droplets for being selected on the "2024 China Pharmaceutical Brand List"!
Date:
03 Jul,2024
The 2024 Misi Conference was grandly held in Huzhou from June 25 to 28, with this year's theme being "Resilience and Progress: Ushering in a New Chapter" At the conference, leveraging MedNet's exclusive, years-long development and operation of its comprehensive database on the market structure across three major channels and six key markets, along with its extensive network of professional readers, the "2024 China Pharma·Brand Rankings" series of lists was unveiled.
Wanbangde Pharmaceutical Group's flagship product, Wanbang Xinnuokang® Ginkgo Leaf Droplets, stands out prominently. Ranked on the "2024 China Pharmaceutical Brand List [Hospital Settings]—Cardiovascular and Cerebrovascular Disease Medications (Traditional Chinese Medicine)" Reportedly, since 2020, Wanbang Xinnuokang® Ginkgo Leaf Droplets have remained at the top of this list for five consecutive years.
"The 2024 China Pharmaceutical & Brand Rankings" is divided into three lists: "Hospital Outlets," "Primary Care Outlets," and "Retail Outlets." Based on sales figures and growth rates of products across these three outlets—gathered from the "Three Major Outlets and Six Key Markets" terminal monitoring data over the past three years, only brands that meet rigorous criteria make it onto the final list for each category.
The primary criteria for being selected for the "2024 China Pharmaceutical & Brand Ranking" are:
1) The product's sales revenue and growth trajectory across the three major distribution channels over the past three years (2021–2023)—specifically, the quantitative data from these channels, reflecting the final demand driven by clinicians and consumers—will be analyzed using robust statistical methods, accounting for 60% of the evaluation.
2) In May 2024, the final list of top-ranked brands was selected through a WeChat vote for the "2024 China Pharmaceutical Brand List" published by Meinian Network, accounting for 40% of the overall weighting.
3) For each category, the top 40% of brands will be selected based on their total scores to make the final shortlist.
Wanbang Xinnaokang® Ginkgo Leaf Droplets
As a first-line medication for the prevention and treatment of cardiovascular and cerebrovascular diseases, Wanbang Xinnuokang® Ginkgo Leaf Dropping Pills is both a National Essential Medicine and a National Medical Insurance product—marking it as an innovative modern Chinese medicine derived from traditional oral formulations. Wanbang Xinnuokang® Ginkgo Leaf Dropping Pills was once included in the Ministry of Science and Technology’s Torch Program and has since earned numerous prestigious accolades, including "National Traditional Chinese Medicine Craftsmanship Brand," "First Batch of High-Quality National Patent Medicines," "First Batch of Famous Zhejiang Medicines," "First Batch of Zhejiang-Produced Chinese Medicines," and "Pharmaceutical Industry Brand Value List—Rising Star Cardiovascular & Cerebrovascular Drug with the Greatest Market Influence." These remarkable achievements underscore the product’s outstanding performance in the market and its widespread recognition among consumers.
Moving forward, Wanbangde Pharmaceutical Group will, inspired by this prestigious honor, uphold the essence of traditional Chinese medicine, relentlessly pursue innovation, strengthen our brand power, and bolster corporate resilience. We’ll leverage our high-quality competitiveness to aggressively expand into the end-market, paving the way for a healthier future in the healthcare industry!
Related Recommendations